[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1178884A1 - - Google Patents

Info

Publication number
HK1178884A1
HK1178884A1 HK13105590.8A HK13105590A HK1178884A1 HK 1178884 A1 HK1178884 A1 HK 1178884A1 HK 13105590 A HK13105590 A HK 13105590A HK 1178884 A1 HK1178884 A1 HK 1178884A1
Authority
HK
Hong Kong
Application number
HK13105590.8A
Inventor
Dieter Kadereit
Matthias Schaefer
Stephanie Hachtel
Axel Dietrich
Thomas Huebschle
Andreas Gille
Katrin Hiss
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1178884A1 publication Critical patent/HK1178884A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK13105590.8A 2010-01-13 2013-05-10 HK1178884A1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305035 2010-01-13
PCT/EP2011/050295 WO2011086075A1 (de) 2010-01-13 2011-01-12 2,5,7-substituierte oxazolopyrimidinderivate

Publications (1)

Publication Number Publication Date
HK1178884A1 true HK1178884A1 (ko) 2013-09-19

Family

ID=41820512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105590.8A HK1178884A1 (ko) 2010-01-13 2013-05-10

Country Status (21)

Country Link
US (1) US8785439B2 (ko)
EP (1) EP2523961B1 (ko)
JP (1) JP5844276B2 (ko)
KR (1) KR101759126B1 (ko)
CN (1) CN102791716B (ko)
AR (1) AR079980A1 (ko)
AU (1) AU2011206611B2 (ko)
BR (1) BR112012017393A2 (ko)
CA (1) CA2791445C (ko)
DK (1) DK2523961T3 (ko)
ES (1) ES2448645T3 (ko)
HK (1) HK1178884A1 (ko)
IL (1) IL220707A (ko)
MX (1) MX2012007835A (ko)
MY (1) MY156525A (ko)
PT (1) PT2523961E (ko)
RU (1) RU2557246C2 (ko)
SG (1) SG183101A1 (ko)
TW (1) TWI485153B (ko)
UY (1) UY33176A (ko)
WO (1) WO2011086075A1 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159857A (en) 2010-01-14 2017-02-15 Sanofi Sa 2,5-substituted oxazolopyrimidine derivatives
PT2523960E (pt) * 2010-01-14 2013-12-09 Sanofi Sa Derivados heterocíclicos de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
WO2011086079A1 (de) * 2010-01-14 2011-07-21 Sanofi-Aventis Carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
JP2018525350A (ja) 2015-07-02 2018-09-06 ホライズン オルファン エルエルシー Ado耐性システアミン類似体およびその使用
EP4106876A1 (en) 2020-02-18 2022-12-28 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
JP2024512771A (ja) 2021-04-16 2024-03-19 ギリアード サイエンシーズ, インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010802A (es) 2003-04-25 2005-12-14 Univ Cardiff Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.
ES2467160T3 (es) * 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
FR2865208B1 (fr) * 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
WO2007061458A2 (en) * 2005-11-23 2007-05-31 Epix Delaware, Inc. S1p receptor modulating compounds and use thereof
EP1900729A1 (en) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
AU2007227278B2 (en) * 2007-03-21 2014-09-11 Epix Pharmaceuticals, Inc. SIP receptor modulating compounds and use thereof
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
US8735387B2 (en) 2008-07-15 2014-05-27 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
UY33178A (es) 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico heteroxíclicos que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
UY33177A (es) 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
PT2523960E (pt) 2010-01-14 2013-12-09 Sanofi Sa Derivados heterocíclicos de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
WO2011086079A1 (de) 2010-01-14 2011-07-21 Sanofi-Aventis Carbonsäurederivate mit einem 2,5-substituierten oxazolopyrimidinring
MY159857A (en) 2010-01-14 2017-02-15 Sanofi Sa 2,5-substituted oxazolopyrimidine derivatives

Also Published As

Publication number Publication date
AU2011206611A1 (en) 2012-08-02
RU2557246C2 (ru) 2015-07-20
US8785439B2 (en) 2014-07-22
WO2011086075A1 (de) 2011-07-21
BR112012017393A2 (pt) 2017-12-12
CA2791445C (en) 2017-08-29
KR20120115544A (ko) 2012-10-18
TW201141873A (en) 2011-12-01
CA2791445A1 (en) 2011-07-21
DK2523961T3 (en) 2014-03-24
EP2523961A1 (de) 2012-11-21
MY156525A (en) 2016-02-26
US20130137685A1 (en) 2013-05-30
ES2448645T3 (es) 2014-03-14
EP2523961B1 (de) 2013-12-18
PT2523961E (pt) 2014-03-20
JP2013517238A (ja) 2013-05-16
CN102791716A (zh) 2012-11-21
UY33176A (es) 2011-08-31
TWI485153B (zh) 2015-05-21
AR079980A1 (es) 2012-03-07
IL220707A0 (en) 2012-08-30
MX2012007835A (es) 2012-07-30
IL220707A (en) 2015-02-26
CN102791716B (zh) 2016-05-11
SG183101A1 (en) 2012-09-27
JP5844276B2 (ja) 2016-01-13
AU2011206611B2 (en) 2015-03-05
KR101759126B1 (ko) 2017-07-18
RU2012134349A (ru) 2014-02-20

Similar Documents

Publication Publication Date Title
BR112013008959A2 (ko)
BR112012031500A2 (ko)
BR112012029986A2 (ko)
BR112012030039A2 (ko)
BR112012019354A2 (ko)
BR112012002126A2 (ko)
BR112012017960A2 (ko)
BR112012025482A2 (ko)
BR112013006400A2 (ko)
BR112012031826A2 (ko)
BR112012023249A2 (ko)
BR112012016456A2 (ko)
BR112012018256A2 (ko)
BR112012023265A2 (ko)
BR112013010949A2 (ko)
BR112013003284A2 (ko)
BR112013002646A2 (ko)
BR112012022788A2 (ko)
BR112012023446A2 (ko)
BR112013006825A2 (ko)
BR112012016895A2 (ko)
BR112013007728A2 (ko)
BR112012030078A2 (ko)
BR112013007731A2 (ko)
BR112012029562A2 (ko)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190107